{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-070355","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2022-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.844100+00:00","generated_at":"2026-06-25T02:15:14.330152+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Onconova promotes Guerin to COO/CFO, Makovski Silverstein to head corp dev; Oler resigns","bullets":["Mark Guerin appointed COO/CFO; salary raised to $475K; receives 50,250 options and 16,500 RSUs.","Dr. Adar Makovski Silverstein promoted to Senior Director and Head of Corporate Development.","Avi Oler, SVP Corporate Development and General Counsel, resigns effective June 17, 2022.","Guerin's equity awards vest over three years: RSUs 33/33/34%, options 1/3 at year 1 then monthly."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-070355","json":"https://secwatch.observer/filing/0001104659-22-070355.json","markdown":"https://secwatch.observer/filing/0001104659-22-070355.md","text":"https://secwatch.observer/filing/0001104659-22-070355.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465922070355/0001104659-22-070355-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465922070355/tm2218255d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T02:15:14.330152+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"63425e07b7","claim":"Abraham N. Oler resigned as Senior Vice President, Corporate Development and General Counsel at Traws Pharma, Inc..","evidence_excerpt":"On June 10, 2022, Abraham N. Oler, Senior Vice President, Corporate Development and General Counsel, notified the company of his resignation effective June 17, 2022 to pursue an opportunity outside the biotechnology sector.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465922070355/0001104659-22-070355-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Senior Vice President, Corporate Development and General Counsel"}],"fact_type":"executive_change"},{"claim_id":"e9f97ce17f","claim":"Mark Guerin was appointed as Chief Operating Officer at Traws Pharma, Inc..","evidence_excerpt":"On June 10, 2022, Onconova Therapeutics, Inc. (the “Company”) appointed Mark Guerin, as Chief Operating Officer in addition to his current role as Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465922070355/0001104659-22-070355-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}